AlloSure is CareDx’s non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury. The test is designed to accurately determine active rejection, enabling better management of kidney transplant patients, and does not require prior genotyping of the donor or recipient. According to the company, AlloSure is the first and only transplant dd-cfDNA test developed specifically for transplant recipients.
“As the leading partner for the transplant ecosystem, our goal is to improve transplant patient outcomes through innovative, noninvasive testing solutions,” CareDx Chairman and CEO Peter Maag said in a statement. “After a thorough review of potential partners, Seven Bridges emerged as a clear scientific and technical leader with a team that helps us to ensure our workflow processing meets the tight turnaround timeframe requirements for transplants.”
Seven Bridges will apply to AlloSure the Seven Bridges Bioinformatics Ecosystem, a solution created to enable scientists to simplify complex analysis and reduce time to result by working in a common environment and automating concurrent processing of workflows efficiently and collaboratively.
Seven Bridges Ecosystem consists of a compliant analytic platform, curated content, transformative algorithms, access to federated data sets and on-demand professional services. Seven Bridges says the Ecosystem‘s holistic approach to bioinformatics allows researchers at top-tier academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical companies to increase R&D efficiency, enhance the hypothesis resolution process, isolate critical biomarkers, and revive a failing clinical trial while reducing computational workflow times and data storage costs.
Through a ‘hybrid’ automation method, Seven Bridges’ technologies will be integrated with CareDx’s on-premise sequencer and environment, with minimal human intervention, with the goal of ultimately mitigating human error.
Seven Bridges says its analytic tools and services guarantee reproducibility and portability by employing an open, standards-based approach using Common Workflow Language (CWL).
“We’re proud to partner with CareDx as a strategic scientific and bioinformatics partner, supporting their current post-transplant surveillance products and future endeavors,” Seven Bridges CEO Bill Moss stated. “We’re thrilled that Seven Bridges is able to accelerate their analysis workflows and ultimately support their efforts to reduce the number of kidney transplant rejections.”
Based in South San Francisco, CA, CareDx is a non-invasive diagnostics maker which focuses on early detection of organ rejection in kidney and heart transplant patients. Yesterday, CareDx said it intended to offer and sell up to $100 million of shares of its common stock in an underwritten public offering, with underwriters being offered a 30-day option to purchase up to an additional $15 million of shares: “We intend to use the net proceeds from this offering for working capital and general corporate purposes.”